Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The company's vision is to expand the reach of cancer immunotherapy by developing treatments that can be combined with other therapeutic modalities, including other immunotherapies, targeted therapies, and chemotherapy. Agenus has a portfolio of checkpoint modulators, including antibodies targeting CTLA-4, PD-1, and TIGIT, as well as a neoantigen vaccine platform. The company is headquartered in Lexington, Massachusetts, and has additional offices in Cambridge, UK, and Basel, Switzerland.